In T2DM, primary care includes pharmacological treatment using insulin sensitizers, insulin secretagogues, alpha-glucosidase inhibitors,and the more recently developed incretin-based treatments and sodium-glucose cotransporter-2 (SGLT2) inhibitors. Here, SLC5A2 is linked to type 2 diabetes mellitus.